Recent studies have also revealed a prominent role of TIL spatial location in the tumor bed and emphasized the relevance of spatial immune heterogeneity in sensitivity/resistance to PD-1 axis blockers in NSCLC (14). The gene discussed is PDCD1; the disease is neoplasm.